Pages that link to "Q73160386"
Jump to navigation
Jump to search
The following pages link to Responses in refractory hairy cell leukemia to a recombinant immunotoxin (Q73160386):
Displaying 33 items.
- Advances in anticancer immunotoxin therapy (Q28085551) (← links)
- Antibody immunotherapy for leukemia (Q34107825) (← links)
- Engineering toxin-resistant therapeutic stem cells to treat brain tumors (Q34444939) (← links)
- Large-scale depletion of CD25+ regulatory T cells from patient leukapheresis samples (Q34657644) (← links)
- Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. (Q34657700) (← links)
- Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell line (Q35214050) (← links)
- Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates (Q35446333) (← links)
- Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy. (Q35653164) (← links)
- Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia (Q36058502) (← links)
- Ability of luteinizing hormone releasing hormone-Pseudomonas aeruginosa exotoxin 40 binding to LHRH receptor on human liver cancer cells (Q36065616) (← links)
- Pseudomonas exotoxin kills Drosophila S2 cells via apoptosis (Q36200380) (← links)
- Immunoconjugates in the management of hairy cell leukemia (Q36328016) (← links)
- Novel Therapy for Atherosclerosis Using Recombinant Immunotoxin Against Folate Receptor β-Expressing Macrophages (Q36366225) (← links)
- Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies (Q37165245) (← links)
- Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity (Q37232738) (← links)
- The role of tregs in glioma-mediated immunosuppression: potential target for intervention. (Q37452411) (← links)
- Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies. (Q37581788) (← links)
- Approach to the patient after relapse of hairy cell leukemia (Q37611080) (← links)
- Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia (Q37623386) (← links)
- Microbial-based therapy of cancer: current progress and future prospects (Q37843621) (← links)
- Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia (Q37877743) (← links)
- Hairy cell leukemia-new genes, new targets (Q38124726) (← links)
- Immunotoxins: a review of their use in cancer treatment (Q38201457) (← links)
- Combining the antimesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cells (Q39046021) (← links)
- Clinical targeting recombinant immunotoxins for cancer therapy (Q41149227) (← links)
- CD21(-/low) marginal zone B cells highly express Fc receptor-like 5 protein and are killed by anti-Fc receptor-like 5 immunotoxins in hepatitis C virus-associated mixed cryoglobulinemia vasculitis. (Q42238468) (← links)
- Improving the in vivo efficacy of an anti-Tac (CD25) immunotoxin by Pseudomonas exotoxin A domain II engineering. (Q52716628) (← links)
- Update on hairy cell leukemia. (Q54979474) (← links)
- Hairy cell leukemia (Q74267091) (← links)
- Immunotoxins for targeted cancer therapy (Q79199423) (← links)
- Hairy cell leukemia (Q80214654) (← links)
- Hairy cell leukemia (Q80731609) (← links)
- Renal Excretion of Recombinant Immunotoxins Containing Pseudomonas Exotoxin (Q83629852) (← links)